Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients with Symptomatic Celiac Disease.

Murray JA, Kelly CP, Green PH, Marcantonio A, Wu TT, Mäki M, Adelman DC; CeliAction Study® Group of Investigators..

Gastroenterology. 2016 Nov 15. pii: S0016-5085(16)35346-X. doi: 10.1053/j.gastro.2016.11.004. [Epub ahead of print]

PMID:
27864127
2.

Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.

Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M.

Dig Dis Sci. 2016 Oct;61(10):2823-30. doi: 10.1007/s10620-016-4219-x.

PMID:
27417565
3.

Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.

Lähdeaho ML, Kaukinen K, Laurila K, Vuotikka P, Koivurova OP, Kärjä-Lahdensuu T, Marcantonio A, Adelman DC, Mäki M.

Gastroenterology. 2014 Jun;146(7):1649-58. doi: 10.1053/j.gastro.2014.02.031.

PMID:
24583059
4.

Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.

Siegel M, Garber ME, Spencer AG, Botwick W, Kumar P, Williams RN, Kozuka K, Shreeniwas R, Pratha V, Adelman DC.

Dig Dis Sci. 2012 Feb;57(2):440-50. doi: 10.1007/s10620-011-1906-5.

PMID:
21948339

Supplemental Content

Loading ...
Support Center